Examkin

Question

Difficulty: HardDepressive Disorders

A 45-year-old man with no prior psychiatric history is diagnosed with Major Depressive Disorder. Over the next two years, his condition proves difficult to manage, requiring escalating interventions based on his varying levels of therapeutic response at each stage. According to evidence-based guidelines for stepped-care psychiatric management, arrange the following clinical interventions in the most appropriate chronological order, progressing from initial presentation to the management of severe treatment-resistant depression.

  1. 1Prescribe an initial selective serotonin reuptake inhibitor (SSRI) and titrate to the maximum tolerated dose over a 4 to 6-week period.
  2. 2Cross-taper to a serotonin-norepinephrine reuptake inhibitor (SNRI) following a complete lack of clinical response to the initial 6-week trial.
  3. 3Add an atypical antipsychotic (e.g., aripiprazole) to the current regimen after observing only a partial clinical response to the second monotherapy.
  4. 4Refer for electroconvulsive therapy (ECT) due to persistent, severe, and functionally impairing symptoms despite multiple optimized medication combinations.

Answer

The correct chronological sequence for managing progressive treatment-resistant depression is: 1) Initial SSRI monotherapy optimization, 2) Switching to a different agent (SNRI) due to complete non-response, 3) Augmenting with an atypical antipsychotic due to partial response, and 4) Proceeding to Electroconvulsive Therapy (ECT) after multiple failed pharmacological trials.
The correct algorithm for depression pharmacotherapy relies on assessing the degree of response at each interval. Initial therapy utilizes an SSRI. If no response is observed after an adequate trial (4-6 weeks at max dose), a switch to a different monotherapy is indicated. If that subsequent trial yields a partial response, guidelines recommend augmenting with agents like aripiprazole, lithium, or thyroid hormone rather than switching again. Finally, if the depression remains functionally debilitating despite these sequential optimized medication trials (true treatment resistance), neuromodulation techniques such as ECT become the definitive standard of care.

Step-by-Step Solution

1
Identify the standard first-line treatment for an initial depressive episode.
Initial SSRI monotherapy and dose optimization is the starting point.
SSRIs have a favorable side effect profile and are the standard of care for initiating MDD treatment.
2
Determine the appropriate action for a complete non-response after an adequate 6-week trial.
Switching to a different monotherapy (e.g., an SNRI) is the next step.
Without any clinical improvement, augmenting is generally less effective than switching entirely to a medication with a potentially different mechanism or receptor binding profile.
3
Determine the appropriate action for a partial clinical response to the second trial.
Augmentation with a second agent (e.g., atypical antipsychotic) is indicated.
When a patient exhibits partial improvement, augmenting allows the clinician to preserve existing therapeutic gains while targeting residual symptoms.
4
Identify the definitive treatment for severe depression that has failed multiple pharmacological steps.
Referral for Electroconvulsive Therapy (ECT).
ECT is the most effective treatment for profound, treatment-resistant depression (failure of 2+ adequate trials of distinct classes/combinations).

Key Concept

Stepped-care management of Major Depressive Disorder (Switching vs. Augmentation vs. Neuromodulation)
Estimated Time:1m 30s
Rate this question

Topics

Depressive Disorders

More questions from this topic